Subject(s)
Acquired Immunodeficiency Syndrome/complications , Skin/pathology , Syphilis/diagnosis , Treponema pallidum/isolation & purification , Female , Humans , Injections, Intramuscular , Penicillin G Benzathine/administration & dosage , Skin/microbiology , Syphilis/drug therapy , Syphilis/microbiology , Young AdultABSTRACT
Slow extended daily dialysis (SLEDD) is the newest form of dialysis that is being used increasingly to replace continuous venovenous hemodialysis (CVVHD) for critically ill patients; it is less expensive to administer and has similar safety for patients who are prone to hemodynamic instability. Unfortunately, there are limited data regarding the appropriate dosing of antimicrobial agents for patients undergoing SLEDD. Furthermore, many nonnephrologists are not familiar with the differences between SLEDD, other continuous renal replacement therapies--for example, CVVHD--and routine hemodialysis. Thus, there is potential for inaccurate and, at worst, inadequate dosing of critical antimicrobial agents for this patient population. We review the available pharmacokinetic data on SLEDD and give preliminary recommendations for how to approach dosing in this situation.
